Thrombolytic therapy: current status - summary
Canadian Coordinating Office for Health Technology Assessment
Record ID 31995000010
English, French
Authors' objectives:
To identify current controversies and emerging trends about thrombolytic therapy, and examine potential impact in Canada
Authors' results and conclusions:
a)The ISIS-3 trial shows no difference in survival between streptokinase, tPA and ASPAC; the debate continues on optimal dosing and administration rates; b) The time between onset of symptoms of AMI and therapy is the most critical factor in achieving significant myocardial salvage and reduced mortality; c) Controversy over patient selection continues; d) There is evidence that adjunctive therapies with anticoagulants or antiplatelets improve efficacy of thrombolytic therapy; e) Approximate costs per treatment are: tPA - $2900, streptokinase - $400, ASPAC - $1900, urokinase - $775. Estimated annual total drug cost in Canada are $77 million (tPA), $51 million (ASPAC) and $12 million (streptokinase).
Authors' recommendations:
Future directions include research into earlier administration, noninvasive detection of reperfusion, enhancement of early patency, prevention of reocclusion and reduction of complications.
Authors' methods:
Review
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/
Year Published:
1992
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Anistreplase
- Myocardial Infarction
- Plasminogen Activators
- Streptokinase
- Tissue Plasminogen Activator
- Urokinase-Type Plasminogen Activator
- Fibrinolytic Agents
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment.
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.